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tatins are an extensively used class of drugs. According to a report from the IMS Institute for Healthcare Informatics, 1 close to 94 million individual prescriptions for generic simvastatin were issued in 2010. Myopathy is an uncommon, but welldescribed side effect of statin therapy. Drug interactions increase the risk of statin-associated myopathy by as much as ten-fold. 2 Statin-associated myopathies generally resolve after discontinuation of the drug; however, in rare cases of statin-associated autoimmune myopathy, symptoms may persist or worsen after the drug is discontinued, requiring immunosuppressive therapy. 3 Polymyositis is a rare side effect of statin therapy that is characterized by symmetric proximal muscle weakness and the persistence of symptoms even after discontinuation of the drug. Here we describe a patient with probable polymyositis in whom drug interactions may have played a role.
Case Presentation
A male patient, aged 59-years, presented in September 2011 with complaints of insidious onset of weakness, muscle soreness, and trouble climbing stairs for 5 months. The patient had symptoms in both upper and lower extremities, but his symptoms were more pronounced in the hip flexors. He described his symptoms as gradually worsening and denied any history of viral illness or fever.
The patient's medical history was significant for ST-elevated myocardial infarction (STEMI) in April 2006, for which he had been treated with percutaneous coronary intervention (PCI) with drug-eluting stent placement and had been started on atorvastatin 20 mg daily; 3 months later gemfibrozil 600 mg twice daily was added. In September 2010, the patient had symptoms of 
Discussion
Statins are used extensively to lower serum cholesterol as well as for primary and secondary prevention of coronary events and stroke. 4 Myopathy is a rare but well-documented side effect associated with statin use and ranges from myalgia to myositis to overt rhabdomyolsis. 5, 6 Onset of muscle symptoms usually occurs within weeks to months of statin therapy initiation, and symptoms resolve within months of drug discontinuation. 7 In addition to the self-limited, toxic myopathy associated with statins, there are reports of statinassociated inflammatory myopathies including polymyositis, dermatomyositis, and necrotizing autoimmune myopathythat are characterized by elevated CK levels and proximal muscle weakness during or after statin use that persists even after discontinuation of the drug. Symptoms improve with immunosuppressive therapy, but many patients require treatment with multiple agents including steroids, steroid-sparing agents, and intravenous immunoglobulin, 21 as in the case reported here. Diagnostic criteria for polymyositis include: symmetric proximal muscle weakness progressing over weeks to months; muscle biopsy demonstrating myofiber necrosis, phagocytosis, regeneration, variation in fiber diameter, and an inflammatory exudate; elevation of serum skeletal muscle enzymes; and electromyography showing low-amplitude, small, polyphasic motor units. 22 The patient presented here meets three of the four diagnostic criteria, making this a probable case of polymyositis.
The histopathological findings described in the muscle biopsies of patients with polymyositis
show necrotic and regenerating muscle fibers with a characteristic endomysial inflammatory Although the clinical presentation of several inflammatory myopathies is similar, histology allows for differentiation of the diagnoses. Histologically, dermatomyositis is similar to polymyositis, except that the infiltrate is composed primarily of CD4 T cells. 3 The characteristic rash is a further distinguishing characteristic. In contrast, necrotizing autoimmune myopathy is notable for the relative absence of inflammatory cells on histology. 
